Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX® Platform Technology - BioSpace
Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX® Platform Technology BioSpace
Published: Jul 30, 2019. $10 million of equity purchased at a premium of approximately 31%; License agreement includes a $15 million up-front payment.
Comments
Post a Comment